NASDAQ:PRAH

PRA Health Sciences (PRAH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$165.21
$165.21
50-Day Range
$165.21
$174.52
52-Week Range
$93.00
$175.95
Volume
57 shs
Average Volume
837,472 shs
Market Capitalization
$10.70 billion
P/E Ratio
50.52
Dividend Yield
N/A
Price Target
N/A
PRAH stock logo

About PRA Health Sciences Stock (NASDAQ:PRAH)

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

PRAH Stock News Headlines

PRA Health Sciences
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
PRAH Historical Data
Western University of Health Sciences
Mercy College of Health Sciences
Mysterious Gold Leverage Just Announced
World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.
Where Do Hedge Funds Stand On Five Below Inc (FIVE)?
See More Headlines
Receive PRAH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PRA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/28/2021
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial Physical Research
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAH
Fax
N/A
Employees
18,100
Year Founded
N/A

Profitability

Net Income
$197.04 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.18 billion
Cash Flow
$6.09 per share
Book Value
$23.06 per share

Miscellaneous

Free Float
N/A
Market Cap
$10.70 billion
Optionable
Optionable
Beta
1.31
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


PRAH Stock Analysis - Frequently Asked Questions

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences, Inc. (NASDAQ:PRAH) announced its earnings results on Wednesday, April, 28th. The medical research company reported $1.35 earnings per share for the quarter, beating analysts' consensus estimates of $1.32 by $0.03. The medical research company had revenue of $933.78 million for the quarter, compared to the consensus estimate of $863.45 million. PRA Health Sciences had a net margin of 6.40% and a trailing twelve-month return on equity of 20.49%. PRA Health Sciences's quarterly revenue was up 19.1% on a year-over-year basis. During the same period last year, the firm posted $1.05 earnings per share.

What is Colin Shannon's approval rating as PRA Health Sciences' CEO?

500 employees have rated PRA Health Sciences Chief Executive Officer Colin Shannon on Glassdoor.com. Colin Shannon has an approval rating of 87% among the company's employees.

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Abbott Laboratories (ABT), Walt Disney (DIS), PayPal (PYPL), Veeva Systems (VEEV), Pfizer (PFE) and AbbVie (ABBV).

When did PRA Health Sciences IPO?

PRA Health Sciences (PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

This page (NASDAQ:PRAH) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners